EFFICACY AND SAFETY OF IRON (III)–HYDROXIDE SUCROSE COMPLEX IN CORRECTION OF ANEMIA STAGE 5D CHRONIC KIDNEYDISEASE HEMODIALYSIS PATIENTS NOT TREATED BY ERYTHROPOIESIS–STIMULATING AGENTS (PROSPECTIVEANALYSIS)
| Autor: | Е. К. Krasjuk, V. F. Krot, І. О. Dudar, О. М. Loboda, І. М. Shifris, V. М. Savchuk, Т. М. Nechiporuk, I. I. Gonchar, F. О. Pruskiy, N. G. Alekseeva |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Anemia Urology medicine.medical_treatment lcsh:RC870-923 Gastroenterology Internal medicine medicine Immunology and Allergy Dialysis chronic kidney disease anemia haemodialysis iron deficiency sucrose complex haemoglobin ferritin transferrin saturation chemistry.chemical_classification biology business.industry Transferrin saturation Biochemistry (medical) Iron deficiency lcsh:Diseases of the genitourinary system. Urology medicine.disease Ferritin chemistry Nephrology Transferrin biology.protein Hemodialysis business Kidney disease |
| Zdroj: | Український Журнал Нефрології та Діалізу, Iss 4(44), Pp 64-69 (2014) |
| ISSN: | 2616-7352 2304-0238 |
| DOI: | 10.31450/ukrjnd.4(44).2014.07 |
| Popis: | The aim of study was to evaluat the efficacy and safety ofSUFER® (iron (III) sucrose complex) in correction of anemia stage 5D chronic kidney disease hemodialysis patients. Methods. This study included thirty patients undergoing regular hemodialysis (mean age 48,81±3,24 years, mean duration of dialysis 30,43±9,25 months) with renal anemia and iron deficiency. All patients were treated with SUFER® intravenously 200 mg three times a week. Correction dose was determined according to the manufacturer’s recommendations. Results. Mean level offerritin was significantly increased from 125,15 ± 21,46 ng / ml to 375,56 ± 64,12 ng / ml (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|